AR060424A1 - Lineas celulares , composiciones para el tratamiento de melanomas que las comprenden procedimientos para preparar las composiciones y metodos de tratamiento - Google Patents

Lineas celulares , composiciones para el tratamiento de melanomas que las comprenden procedimientos para preparar las composiciones y metodos de tratamiento

Info

Publication number
AR060424A1
AR060424A1 ARP070101520A ARP070101520A AR060424A1 AR 060424 A1 AR060424 A1 AR 060424A1 AR P070101520 A ARP070101520 A AR P070101520A AR P070101520 A ARP070101520 A AR P070101520A AR 060424 A1 AR060424 A1 AR 060424A1
Authority
AR
Argentina
Prior art keywords
compositions
treatment
mel
microorganisms
deposited
Prior art date
Application number
ARP070101520A
Other languages
English (en)
Spanish (es)
Inventor
Euw Erika Maria Von
Jose Mordoh
Maria Marcela Barrio
Original Assignee
Consejo Nac Invest Cient Tec
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Consejo Nac Invest Cient Tec filed Critical Consejo Nac Invest Cient Tec
Priority to ARP070101520A priority Critical patent/AR060424A1/es
Priority to NZ580533A priority patent/NZ580533A/xx
Priority to PCT/IB2008/051385 priority patent/WO2008126039A2/en
Priority to AU2008238909A priority patent/AU2008238909B2/en
Priority to KR1020097022846A priority patent/KR101502518B1/ko
Priority to CA2683629A priority patent/CA2683629C/en
Priority to BRPI0809767-4A priority patent/BRPI0809767B1/pt
Priority to ES08737810T priority patent/ES2390130T3/es
Priority to MX2009010927A priority patent/MX2009010927A/es
Priority to EP08737810A priority patent/EP2146742B1/en
Priority to US12/450,721 priority patent/US8501168B2/en
Priority to RU2009141593/10A priority patent/RU2484134C2/ru
Priority to CN2008800182498A priority patent/CN101861163B/zh
Priority to JP2010502629A priority patent/JP5762738B2/ja
Priority to DK08737810.5T priority patent/DK2146742T3/da
Publication of AR060424A1 publication Critical patent/AR060424A1/es
Priority to ZA200907240A priority patent/ZA200907240B/xx
Priority to CO09121156A priority patent/CO6260100A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00119—Melanoma antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4271—Melanoma antigens
    • A61K40/4272—Melan-A/MART
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4271—Melanoma antigens
    • A61K40/4273—Glycoprotein 100 [Gp100]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N13/00—Treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic waves
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/876—Skin, melanoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ARP070101520A 2007-04-11 2007-04-11 Lineas celulares , composiciones para el tratamiento de melanomas que las comprenden procedimientos para preparar las composiciones y metodos de tratamiento AR060424A1 (es)

Priority Applications (17)

Application Number Priority Date Filing Date Title
ARP070101520A AR060424A1 (es) 2007-04-11 2007-04-11 Lineas celulares , composiciones para el tratamiento de melanomas que las comprenden procedimientos para preparar las composiciones y metodos de tratamiento
ES08737810T ES2390130T3 (es) 2007-04-11 2008-04-11 Líneas celulares, composiciones que las comprenden para el tratamiento de los melanomas, procedimientos para preparar las composiciones y métodos de tratamiento
US12/450,721 US8501168B2 (en) 2007-04-11 2008-04-11 Cell lines, compositions comprising them for the treatment of melanomas, procedures to prepare the compositions, and treatment methods
AU2008238909A AU2008238909B2 (en) 2007-04-11 2008-04-11 Cell lines, compositions comprising them for the treatment of melanomas, procedures to prepare the compositions, and treatment methods
KR1020097022846A KR101502518B1 (ko) 2007-04-11 2008-04-11 세포주, 이를 포함하는 흑색종의 치료를 위한 조성물, 조성물 제조방법 및 치료방법
CA2683629A CA2683629C (en) 2007-04-11 2008-04-11 Cell lines, compositions comprising them for the treatment of melanomas, procedures to prepare the compositions, and treatment methods
BRPI0809767-4A BRPI0809767B1 (pt) 2007-04-11 2008-04-11 Composição para o tratamento do melanoma, composição para o tratamento de melanomas humanos, procedimento para preparação da composição e procedimento para preparar a composição para tratamento de melanomas humanos
NZ580533A NZ580533A (en) 2007-04-11 2008-04-11 Cell lines, compositions comprising them for the treatment of melanomas, procedures to prepare the compositions, and treatment methods
MX2009010927A MX2009010927A (es) 2007-04-11 2008-04-11 Lineas celulares, composiciones para el tratamiento de melanomas que las comprenden, procedimientos para preparar las composiciones, y metodos de tratamiento.
EP08737810A EP2146742B1 (en) 2007-04-11 2008-04-11 Cell lines, compositions comprising them for the treatment of melanomas, procedures to prepare the compositions, and treatment methods
PCT/IB2008/051385 WO2008126039A2 (en) 2007-04-11 2008-04-11 Cell lines, compositions comprising them for the treatment of melanomas, procedures to prepare the compositions, and treatment methods
RU2009141593/10A RU2484134C2 (ru) 2007-04-11 2008-04-11 Клеточные линии, содержащие их композиции для лечения меланом, способы получения композиций и способы лечения
CN2008800182498A CN101861163B (zh) 2007-04-11 2008-04-11 用于治疗黑素瘤的细胞系、含有它们的组合物、制备所述组合物的方法以及治疗方法
JP2010502629A JP5762738B2 (ja) 2007-04-11 2008-04-11 細胞株、黒色腫の治療のためにそれを含む組成物、組成物の製造手順および治療方法
DK08737810.5T DK2146742T3 (da) 2007-04-11 2008-04-11 Cellelinjer, sammensætninger omfattende disse til behandling af melanomer, fremgangsmåder til at fremstille sammensætningerne og behandlingsmetoder
ZA200907240A ZA200907240B (en) 2007-04-11 2009-10-16 Cell lines, compositions comprising them for the treatment of melanomas, procedures to prepare the compositions, and treatment methods
CO09121156A CO6260100A2 (es) 2007-04-11 2009-10-28 Lineas celulares composiciones pera el tratamiento de melanomas que las comprenden procedimiento para preparar las composiciones y metodos de tratamiento

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ARP070101520A AR060424A1 (es) 2007-04-11 2007-04-11 Lineas celulares , composiciones para el tratamiento de melanomas que las comprenden procedimientos para preparar las composiciones y metodos de tratamiento

Publications (1)

Publication Number Publication Date
AR060424A1 true AR060424A1 (es) 2008-06-18

Family

ID=39590605

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070101520A AR060424A1 (es) 2007-04-11 2007-04-11 Lineas celulares , composiciones para el tratamiento de melanomas que las comprenden procedimientos para preparar las composiciones y metodos de tratamiento

Country Status (17)

Country Link
US (1) US8501168B2 (cg-RX-API-DMAC7.html)
EP (1) EP2146742B1 (cg-RX-API-DMAC7.html)
JP (1) JP5762738B2 (cg-RX-API-DMAC7.html)
KR (1) KR101502518B1 (cg-RX-API-DMAC7.html)
CN (1) CN101861163B (cg-RX-API-DMAC7.html)
AR (1) AR060424A1 (cg-RX-API-DMAC7.html)
AU (1) AU2008238909B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0809767B1 (cg-RX-API-DMAC7.html)
CA (1) CA2683629C (cg-RX-API-DMAC7.html)
CO (1) CO6260100A2 (cg-RX-API-DMAC7.html)
DK (1) DK2146742T3 (cg-RX-API-DMAC7.html)
ES (1) ES2390130T3 (cg-RX-API-DMAC7.html)
MX (1) MX2009010927A (cg-RX-API-DMAC7.html)
NZ (1) NZ580533A (cg-RX-API-DMAC7.html)
RU (1) RU2484134C2 (cg-RX-API-DMAC7.html)
WO (1) WO2008126039A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200907240B (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6077735B2 (ja) * 2011-06-08 2017-02-08 日本電子株式会社 電子顕微鏡観察用染色剤および電子顕微鏡観察用試料の染色方法
SG11201401631VA (en) 2011-10-20 2014-05-29 California Stem Cell Inc Antigen presenting cancer vaccine with gamma interferon
JP6077757B2 (ja) * 2012-04-17 2017-02-08 日本電子株式会社 電子顕微鏡観察用染色剤および電子顕微鏡観察用試料の染色方法
JP5921386B2 (ja) * 2012-08-27 2016-05-24 日本電子株式会社 電子顕微鏡観察用染色剤および電子顕微鏡観察用試料の染色方法
CN103146641B (zh) * 2013-02-06 2015-03-25 云南中科灵长类生物医学重点实验室 多能干细胞的传代方法及其用途
CN104990781B (zh) * 2015-06-29 2018-02-16 中国医学科学院皮肤病研究所 黑素细胞免疫组化苏木素—甲苯胺蓝双重复染法
AU2020395765A1 (en) 2019-12-03 2022-06-16 Neuvogen, Inc. Tumor cell vaccines
RU2755233C1 (ru) * 2021-01-11 2021-09-14 Сергей Анатольевич Яргунин Способ лечения меланомы кожи IIb-IIc стадий
CN115074328B (zh) * 2022-06-21 2025-02-07 中国人民解放军空军军医大学 一种用于治疗黑素瘤的细胞株及其多效价全细胞疫苗与使用方法
WO2025224605A1 (en) 2024-04-23 2025-10-30 Consejo Nacional De Investigaciones Científicas Y Técnicas (Conicet) Sequential administration of anti-melanoma vaccine and anti-pd-1 monoclonal antibodies

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5882654A (en) * 1989-11-03 1999-03-16 Morton; Donald L. Polyvalent melanoma vaccine
KR20000022445A (ko) * 1996-07-10 2000-04-25 크리스토퍼 엘. 와이트, 스코트 지. 홀퀴스트, 스티븐 엘. 말라스카 수상돌기 세포의 활성화 방법
AU3889997A (en) * 1996-08-16 1998-03-06 Johns Hopkins University School Of Medicine, The Melanoma cell lines expressing shared immunodominant melanoma antigens nd methods of using same
WO1999042564A2 (en) * 1998-02-20 1999-08-26 The Rockefeller University Apoptotic cell-mediated antigen presentation to dendritic cells
US7988963B1 (en) * 1999-10-15 2011-08-02 Baylor Research Institute Use of allogeneic cell lines to load antigen presenting cells to elicit or eliminate immune responses
WO2001028583A2 (en) * 1999-10-18 2001-04-26 St. Vincent's Hospital And Medical Center Of New York Melanoma vaccine and methods of making and using same
US7015205B1 (en) * 1999-10-18 2006-03-21 St. Vincent's Hospital And Medical Center Of New York Melanoma vaccine and methods of making and using same
WO2001048154A1 (en) * 1999-12-28 2001-07-05 Toyoshima, Kumao Maturation-promoting agent for immature dendritic cells
EP1326961B1 (en) * 2000-09-15 2007-08-22 Ortho-McNeil Pharmaceutical, Inc. Compositions and methods for inducing specific cytolytic t cell responses
US20030072737A1 (en) * 2000-12-29 2003-04-17 Michael Brines Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
IL140796A0 (en) * 2001-01-08 2002-02-10 Hadasit Med Res Service An autologous anti-cancer vaccine
CA2440229A1 (en) * 2001-03-09 2002-09-19 Baylor Research Institute Method of treating malignancies through induction of blood immune responses
US7354909B2 (en) * 2001-08-14 2008-04-08 The United States Of America As Represented By Secretary Of The Department Of Health And Human Services Method for rapid generation of mature dendritic cells
EP1451305A4 (en) * 2001-11-07 2005-10-05 Mannkind Corp EPITOPE SYNCHRONIZATION IN CELLS THAT HAVE ANTIGENS
CN102600461B (zh) * 2002-12-06 2017-07-14 西北生物治疗药物公司 给予体外部分成熟的树突细胞治疗肿瘤
EP1623011B1 (en) * 2003-05-09 2013-01-02 Janssen Biotech, Inc. Il-23p40 specific immunoglobulin derived proteins, compositions, methods and uses
JP5021309B2 (ja) * 2003-10-16 2012-09-05 ステファン ジョン ラルフ 免疫調節性組成物およびその使用方法
RU2262941C2 (ru) 2004-01-05 2005-10-27 Государственное учреждение Научно-исследовательский институт клинической иммунологии СО РАМН Способ иммунотерапии злокачественных опухолей головного мозга
EP1740946B1 (en) * 2004-04-20 2013-11-06 Genmab A/S Human monoclonal antibodies against cd20
CA2565874C (en) * 2004-05-10 2017-10-03 Macrogenics, Inc. Humanized fc.gamma.riib-specific antibodies and methods of use thereof
RU2283129C1 (ru) 2004-12-24 2006-09-10 Сергей Викторович Луценко Белковопептидный противоопухолевый композит, клеточный препарат, активированный этим композитом, и способ профилактики или лечения опухолей

Also Published As

Publication number Publication date
KR101502518B1 (ko) 2015-03-13
US20100183683A1 (en) 2010-07-22
JP5762738B2 (ja) 2015-08-12
MX2009010927A (es) 2010-02-11
WO2008126039A3 (en) 2008-12-11
CA2683629A1 (en) 2008-10-23
EP2146742B1 (en) 2012-07-11
JP2010523141A (ja) 2010-07-15
RU2484134C2 (ru) 2013-06-10
ES2390130T3 (es) 2012-11-06
BRPI0809767A2 (pt) 2014-09-23
US8501168B2 (en) 2013-08-06
ZA200907240B (en) 2010-07-28
BRPI0809767B1 (pt) 2022-04-12
WO2008126039A2 (en) 2008-10-23
CN101861163A (zh) 2010-10-13
RU2009141593A (ru) 2011-05-20
NZ580533A (en) 2012-08-31
CO6260100A2 (es) 2011-03-22
CN101861163B (zh) 2013-06-12
AU2008238909A1 (en) 2008-10-23
CA2683629C (en) 2016-06-21
DK2146742T3 (da) 2012-10-22
KR20090129501A (ko) 2009-12-16
EP2146742A2 (en) 2010-01-27
AU2008238909B2 (en) 2013-11-07

Similar Documents

Publication Publication Date Title
MX2009010927A (es) Lineas celulares, composiciones para el tratamiento de melanomas que las comprenden, procedimientos para preparar las composiciones, y metodos de tratamiento.
MY159971A (en) Multipotent/pluripotent cells and methods
MX2020005849A (es) Células madre y progenitoras hematopoyéticas humanas cd34+ modificadas con crispr-cas9 y sus usos.
Burr et al. Mesenchymal stromal cells and regulatory T cells: the Yin and Yang of peripheral tolerance?
MX2021000607A (es) Células t con receptor de antígeno quimérico derivadas de células madre pluripotentes inmunomodificadas.
MX2009014273A (es) Metodos y composiciones para expansion e implantacion optimizadas de celulas madre mesenquimales.
AR080030A1 (es) Tratamiento de tipos de cancer oseo mediante el uso de celulas madre placentarias
MX2016013747A (es) Métodos para aislar, cultivar y diseñar genéticamente poblaciones de células inmunes para terapia adoptiva.
Devitt et al. Successful isolation of viable adipose‐derived stem cells from human adipose tissue subject to long‐term cryopreservation: positive implications for adult stem cell‐based therapeutics in patients of advanced age
NZ593364A (en) Pharmaceutical preparation comprising supernatant of blood mononuclear cell culture
GB2434157A (en) Platelets from stem cells
BR112014032074A2 (pt) construções de tecido conjuntivo tridimensionais engendradas e métodos de fabricar as mesmas
AR080816A1 (es) Preparacion derivada de un cultivo in vitro de celulas de argan no evocadas desdiferenciadas, su uso para el tratamiento del envejecimiento, la inflamacion y curacion de la piel, y metodo para su obtencion
MX339068B (es) Metodos y composiciones para el tratamiento de defectos oseos con poblaciones de celulas placentarias.
WO2015154012A8 (en) Clonogenic natural killer (nk) cell populations and methods of producing and using such populations
BR112022004562A2 (pt) Método de seleção de doador universal para identificar doadores de células nk
CO6761392A2 (es) Administración de proteínas a partir de microportadores de células madre
MX337480B (es) Celulas madre del revestimiento de cordon umbilical y metodos y material para aislar y cultivar las mismas.
WO2008134305A3 (en) Tissue engineering devices and methods for luminal organs
WO2015181831A3 (en) A method for targettingglioblastoma with wharton jelly-mesenchymal stem cells (wj-msc) derived from human umbilical cord
CL2013000893A1 (es) Medio para cultivo de celulas de mamiferos que comprende sobrenadante de la etapa i del fraccionamiento de cohn; procedimiento de preparacion del medio; uso del medio de cultivo para cultivar celulas de mamiferos.
Maheswarappa et al. Prodigiosin as anticancer drug produced from bacteria of termite gut
JP2010523141A5 (cg-RX-API-DMAC7.html)
BR112022003045A2 (pt) Métodos para determinar a adequação de tecido de timo cultivado para o implante em humanos e métodos de uso associados
DK2040560T3 (da) Cysteingranuler og anvendelse deraf som bifidobacterium animalis lactis vækststimulanter

Legal Events

Date Code Title Description
FG Grant, registration